Correction: Serwotka-Suszczak, A. M. et al. A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells. Int. J. Mol. Sci. 2017, 18, 401.

It has been brought to our attention that the affiliation of Dr. Jerzy Pieczykolan at the time when he was responsible for the work described in the paper [...].

It has been brought to our attention that the affiliation of Dr. Jerzy Pieczykolan at the time when he was responsible for the work described in the paper [1] was not mentioned in the previous published version.

We would like to change the Dr. Jerzy Pieczykolan’ affiliation on Page 1 of paper [1] from:

Preclinical Development Department, R&D Celon Pharma Inc., 05-092 Lomianki/Kielpin, Poland; jerzy.pieczykolan@celonpharma.com.

to the correct version, as follows:

Drug Discovery Department, Adamed Group, Czosnow 05-152, Poland; jerzy.pieczykolan@adamed.com.pl.

And add the following affiliation as the current address of Dr. Jerzy Pieczykolan:

Preclinical Development Department, R&D Celon Pharma Inc., 05-092 Lomianki/Kielpin, Poland; jerzy.pieczykolan@celonpharma.com.

This correction does not cause any changes to results and conclusions in the original published paper.